AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informationalB My buyS My sell
Description
Company and Business Model
Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.
Investment Profile
Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.
Fundamental metrics (experimental)Updated: 2026-09-06
EPS (TTM) — earnings per share for the last 12 months, $
29.85
Revenue QoQ — quarter-over-quarter revenue growth
16.0%
EPS surprise
30.9%
20d volatility
1.8%
Dividend yield
0.6%
last ex-date
2026-08-14
AI recommendation changes
Date
Before
After
Reason
2026-09-06
Buy
Hold
Mixed performance; cautious due to high risk factors.
2026-08-06
Hold
Buy
Strong fundamentals and positive momentum support growth outlook.
2026-07-31
Buy
Hold
Weak momentum and high risk; cautious approach advised.
2026-05-18
Hold
Buy
Strong fundamentals and positive short-term momentum.
2026-05-10
Buy
Hold
Weak momentum and high risk; mixed analyst signals.
2026-05-08
—
Buy
Solid fundamentals but mixed momentum signals.
2026-05-08
Buy
Buy
Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29
Hold
Buy
Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17
Buy
Hold
Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09
Hold
Buy
Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22
Buy
Hold
Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06
Hold
Buy
Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29
Buy
Hold
Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion highlights the pharmaceutical industry's growing interest in psychedelic drugs as viable treatments for mental health disorders, particularly treatment-resistant depression. This move signals a potential shift in the market, as positive clinical trial results and regulatory support pave the way for broader acceptance and commercialization of these therapies.
Premarket trading saw significant movements, particularly for UnitedHealth and AtaiBeckley, which reported strong earnings and acquisition news, respectively, impacting investor sentiment and stock valuations.
Eli Lilly's acquisition of AtaiBeckley for $2.8 billion highlights the growing interest in psychedelic drugs as potential treatments for mental health issues, particularly treatment-resistant depression.
Despite the introduction of new GLP-1 drugs and Medicare coverage for obesity, employer coverage for these medications remains stagnant, primarily due to high costs. This trend could impact the market for GLP-1 drugs and the overall healthcare landscape as employers seek alternative ways to support employee health.
UBS recommends that investors consider adding low volatility stocks to their portfolios following a strong first half of 2026 for the S&P 500, which rose 9.6%. This strategy aims to mitigate potential market turbulence as investors navigate ongoing economic uncertainties.
The recent market downturn, particularly in technology stocks, has prompted a shift towards safer investments, with healthcare and financial sectors showing resilience. Jim Cramer highlights potential buying opportunities in fundamentally strong companies amidst this volatility.
Investors are encouraged by a strong stock market performance and specific opportunities in semiconductor and aerospace sectors, particularly with companies like Micron and Honeywell Aerospace showing potential for significant growth.
The Supreme Court's recent rulings and the Dow Jones Industrial Average reaching a historic milestone are significant developments for investors, indicating potential shifts in regulatory power and market dynamics.
Medicare's new coverage for obesity drugs marks a significant shift in healthcare access for older Americans, potentially benefiting millions who previously could not afford these medications. This change could greatly impact companies like Novo Nordisk and Eli Lilly as they tap into a new patient demographic.
Eli Lilly and Regeneron have been selected for the FDA's PreCheck pilot program, aimed at expediting the review process for new pharmaceutical manufacturing facilities, which could significantly reduce approval times and enhance domestic drug production.
